Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor
Interventions: DRUG: moxifloxacin hydrochloride|DRUG: Placebo
Sponsor: OHSU Knight Cancer Institute
Collaborators: National Cancer Institute (NCI)